The immune checkpoint inhibitors (ICI) opened a new era in anticancer treatment. This type of treatment is beneficial for a subset of patients who had a restricted success in the past. However, manipulation of the immune system may lead to the flare up of preexisting autoimmune diseases, requiring intervention. Furthermore, immune suppression strongly influences the outcome of ICI treatment. The ICI treatment of cancer patients with autoimmune disease is a complex task: pre-treatment assessment of the patients, early management of flare ups, and introduction of effective immune suppression is required to achieve the best outcome.
|Translated title of the contribution||Possibilities of immunotherapy in cancer patients with autoimmune disease|
|Number of pages||4|
|Publication status||Published - Jan 1 2019|
ASJC Scopus subject areas